Form 4: Spero Therapeutics Officer Sells Shares for Tax Obligations
Insider Transaction Report
Spero Therapeutics' multi-titled officer, Esther Rajavelu, sold 40,270 shares of common stock at $2.37 per share to cover tax withholding obligations related to RSU vesting.
Summary
- Esther Rajavelu, an officer of Spero Therapeutics, Inc. (SPRO), reported a sale of 40,270 shares of common stock.
- The transaction occurred on November 7, 2025, at a price of $2.37 per share.
- The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) granted to Ms. Rajavelu on November 13, 2023.
- Following this transaction, Ms. Rajavelu beneficially owns 869,450 shares of Spero Therapeutics common stock.
- Ms. Rajavelu holds the titles of Chief Executive Officer, Chief Financial Officer, and Chief Business Officer.
Sentiment
Score: 5
Explanation: The transaction is a routine 'sell to cover' for tax withholding obligations related to RSU vesting, which is generally considered a neutral event and not indicative of management's sentiment towards the company's future performance.
Future Outlook
The filing does not contain any forward-looking statements or guidance.
Industry Context
This Form 4 filing reports a routine insider transaction for tax purposes and does not provide information related to broader industry trends or competitive landscape.
Related Party Transactions
- The reported transaction is an insider sale of common stock by an officer of Spero Therapeutics, Inc. to cover tax withholding obligations related to RSU vesting.
Stakeholder Impact
- Shareholders: The sale of shares by an officer for tax purposes is a common occurrence and typically has minimal direct impact on existing shareholders, as it is not a discretionary sale reflecting a change in confidence.
- Employees: The vesting of RSUs and subsequent 'sell to cover' transaction is a standard component of executive compensation, reflecting the company's compensation structure.
Key Dates
| Date | Description |
|---|---|
| 11/13/2023 | Date Restricted Stock Units (RSUs) were granted to the Reporting Person. |
| 11/07/2025 | Date of transaction (sale of common stock). |
| 11/12/2025 | Date the Form 4 was signed and filed. |
Keywords
Spero Therapeutics, SPRO, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, Esther Rajavelu
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.